INNA-051
From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Vaccine candidate against COVID-19
| Clinical data | |
|---|---|
| Routes of administration | Intranasal |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg){kind=small} COVID-19 portal |
INNA-051 is a COVID-19 vaccine candidate developed by Ena Respiratory.[1][2]
References
- ^ "INNA-051 intranasal safety and tolerability study". anzctr.org.au. 21 April 2021. ACTRN12621000607875p. Retrieved 20 May 2021.
- ^ Clinical trial number NCT05118763 for "Intranasal INNA-051 for Prevention of COVID-19 in Adults" at ClinicalTrials.gov
Scholia has a profile for INNA-051 (Q110269792).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=INNA-051&oldid=1222486823"
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from December 2021
- Infobox drug articles without a structure image
- Infobox drug articles with contradicting parameter input
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles